With 1.91 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.78 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $42.93 whereas the lowest price it dropped to was $41.06. The 52-week range on RARE shows that it touched its highest point at $60.37 and its lowest point at $37.02 during that stretch. It currently has a 1-year price target of $92.95. Beta for the stock currently stands at 0.59.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RARE was down-trending over the past week, with a drop of -1.75%, but this was down by -9.45% over a month. Three-month performance dropped to -20.69% while six-month performance rose 2.82%. The stock lost -9.41% in the past year, while it has gained 1.40% so far this year. A look at the trailing 12-month EPS for RARE yields -6.46 with Next year EPS estimates of -5.14. For the next quarter, that number is -1.37. This implies an EPS growth rate of 23.78% for this year and 18.32% for next year. EPS is expected to grow by 37.90% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -15.75%.
Float and Shares Shorts:
At present, 92.24 million RARE shares are outstanding with a float of 83.36 million shares on hand for trading. On 2024-12-13, short shares totaled 3.71 million, which was 401.99999999999994 higher than short shares on 1731628800. In addition to Dr. Emil D. Kakkis M.D., Ph.D. as the firm’s Founder, President, CEO & Director, Mr. Howard Horn serves as its Executive VP of Corporate Strategy & CFO.
Institutional Ownership:
Through their ownership of 0.97416 of RARE’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, RARE reported revenue of $139494000.0 and operating income of -$131987000.0. The EBITDA in the recently reported quarter was -$109422000.0 and diluted EPS was -$1.4.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RARE since 16 analysts follow the stock currently. There are 14 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RARE analysts setting a high price target of 140.0 and a low target of 48.0, the average target price over the next 12 months is 92.95238. Based on these targets, RARE could surge 228.18% to reach the target high and rise by 12.52% to reach the target low. Reaching the average price target will result in a growth of 117.89% from current levels.
Analysts have provided yearly estimates in a range of -$6.04481 being high and -$6.7852 being low. For RARE, this leads to a yearly average estimate of -$6.28823.
